ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CGEN Compugen Ltd

1.87
-0.04 (-2.09%)
After Hours
Last Updated: 21:30:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Compugen Ltd NASDAQ:CGEN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.04 -2.09% 1.87 1.85 1.89 1.94 1.84 1.94 391,593 21:30:00

Compugen to Present at Jefferies 2014 Global Healthcare Conference in London

12/11/2014 12:01pm

Business Wire


Compugen (NASDAQ:CGEN)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Compugen Charts.

Compugen Ltd. (NASDAQ: CGEN) today announced that Dr. Anat Cohen-Dayag, President and Chief Executive Officer of Compugen, will present a corporate overview and update at the Jefferies 2014 Global Healthcare Conference in London, UK.

The Compugen presentation is scheduled to start at 10:40 a.m. GMT on Thursday, November 20, 2014. The presentation will be available online on the Investors page of the Company’s website. An archive of the event will also be available for a period of 90 days after the presentation.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of oncology and immunology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in South San Francisco is developing monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.

Compugen Ltd.Tsipi Haitovsky, +972-52-598-9892Global Media Liaisontsipih@cgen.com

1 Year Compugen Chart

1 Year Compugen Chart

1 Month Compugen Chart

1 Month Compugen Chart